Anti-cholesterol vaccine - EntreMed

Drug Profile

Anti-cholesterol vaccine - EntreMed

Latest Information Update: 21 Dec 2004

Price : $50

At a glance

  • Originator EntreMed
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 21 Dec 2004 Discontinued - Preclinical for Hypercholesterolaemia in USA (unspecified route)
  • 29 Apr 2003 EntreMed is set to close a $US10.25 million equity deal to support development of several of its programmes
  • 18 Nov 2002 Supended - Preclinical for Hypercholesterolaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top